This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Pulmonary atresia Pulmonary Artery Atresia
1. History
Pulmonary artery atresia is one of the severe cyanotic congenital heart defects and was first described in autopsy reports in the late 19th century. In 1945, when Blalock and Taussig introduced the subclavian artery-to-pulmonary artery shunt (Blalock-Taussig shunt), a turning point was reached in the palliative treatment of patients with cyanotic heart defects. This procedure greatly improved the survival of patients with heart defects with reduced pulmonary blood flow, such as pulmonary atresia and tetralogy of Fallot.
Pulmonary atresia shows various anatomic forms and is broadly divided according to the presence of a ventricular septal defect into ① the type with ventricular septal defect (PA/VSD, the extreme form of tetralogy of Fallot) and ② the type without ventricular septal defect (PA/IVS, intact interventricular septum). PA/IVS has a distinctive pathophysiology because it is accompanied by right ventricle-to-coronary artery fistulas (RVCA fistula) and right ventricle-dependent coronary circulation (RVDCC).
Since the 1990s, percutaneous balloon pulmonary valvuloplasty and radiofrequency perforation techniques have been introduced, making it possible to open the atretic pulmonary valve in a minimally invasive manner. Complete surgical repair is approached through right ventricular outflow tract reconstruction in PA/VSD, and through single-ventricle palliation or biventricular repair in PA/IVS.
2. Causes
The causes of pulmonary atresia differ somewhat according to morphologic type.
PA/IVS (intact ventricular septum):
As fusion and atresia of the pulmonary valve commissures progress during fetal life, blood flow from the right ventricle is blocked.
Blocked flow makes the right ventricle hypertensive, and right ventricle-to-coronary artery fistulas form so that the coronary arteries are supplied retrogradely from the right ventricle.
Right ventricular size varies greatly (from extremely hypoplastic to normal or larger), and tricuspid valve size and right ventricular size determine prognosis.
PA/VSD (with ventricular septal defect):
The extreme form of tetralogy of Fallot, in which underdevelopment of the right ventricular outflow tract is even more severe.
Pulmonary blood flow depends on the ductus arteriosus or major aortopulmonary collateral arteries (MAPCA).
There is a strong association with 22q11 microdeletion (DiGeorge/velocardiofacial syndrome).
Genetic factors: may be associated with NKX2.5, GATA4, JAG1 (Alagille syndrome), 22q11.2 deletion and others. Maternal diabetes, lupus and anticonvulsant exposure are also known risk factors.
3. Genetics
The genetics of pulmonary atresia differ according to the type of associated anomalies.
22q11.2 deletion is found in about 20–30% of PA/VSD patients.
The 22q11.2 deletion includes the TBX1 gene and is accompanied by cardiovascular anomalies (conotruncal septal defects, aortic arch anomalies), immunodeficiency (thymic aplasia), hypoparathyroidism, palatal anomalies and learning disabilities.
Diagnosis: FISH or CMA
JAG1 variants (Alagille syndrome):
Caused by JAG1 or NOTCH2 variants and accompanied by peripheral pulmonary artery stenosis/atresia, biliary hypoplasia, characteristic facies, vertebral anomalies and eye anomalies.
Others:
CHARGE syndrome (CHD7 variants): pulmonary artery anomalies may be associated
VACTERL association: rarely accompanied by pulmonary artery anomalies
Down syndrome (trisomy 21): some accompanied by pulmonary artery anomalies
PA/IVS often occurs in isolation, and its association with specific genetic syndromes is lower than that of PA/VSD. Chromosomal microarray and next-generation sequencing (NGS panel) are recommended for comprehensive genetic evaluation.
4. General epidemiology
Pulmonary atresia is relatively rare among congenital heart defects.
PA/IVS:
Incidence: about 4–8 per 100,000 births
About 1–3% of all congenital heart defects
Sex: some reports that it is slightly more common in boys
PA/VSD:
About 15–20% of all tetralogy of Fallot (TOF)
Considering the incidence of TOF (about 35 per 100,000), PA/VSD is estimated at about 5–7 per 100,000
Anatomic variability is very large when MAPCAs are present
In Korea, several dozen patients are diagnosed annually under code Q25.5, and it is eligible for Special Copayment Reduction V149. Because intensive treatment at specialized pediatric cardiac centers is required, most patients are concentrated in tertiary hospitals in Seoul and the capital region.
With the spread of prenatal ultrasound, the prenatal diagnosis rate has increased, and prenatal diagnosis is advantageous for planning delivery and initial treatment.
5. Pathophysiology
The pathophysiology of pulmonary atresia differs greatly by type.
Pathophysiology of PA/IVS:
Because of pulmonary valve atresia, there is no blood flow from the right ventricle to the pulmonary artery. The pulmonary circulation is supplied retrogradely from the aorta to the pulmonary artery through the ductus arteriosus (ductus-dependent pulmonary circulation).
The right ventricle has no outlet and becomes hypertensive, and regurgitation (TR) occurs through the tricuspid valve. High pressure within the right ventricle opens coronary sinusoids, forming right ventricle-to-coronary artery fistulas (RVCA fistula).
In some patients, the coronary arteries become completely dependent on the right ventricle for their blood supply, resulting in RVDCC (right ventricular dependent coronary circulation). In this case, right ventricular decompression surgery can cause coronary ischemia, which has an important impact on the treatment approach.
Pathophysiology of PA/VSD:
There is a left-to-right shunt at the ventricular level, but because the pulmonary artery is atretic, pulmonary blood flow is supplied only through MAPCAs or the ductus arteriosus.
MAPCAs vary in caliber, number and site of origin and supply blood independently to each lung segment. Some MAPCAs are connected (confluent) with the true pulmonary arteries, and some are independent.
If stenosis develops within a MAPCA, the corresponding lung segment is underperfused; conversely, if there is no stenosis, the pulmonary vessels are exposed to high pressure and pulmonary vascular disease progresses.
6. Symptoms
The symptoms of pulmonary atresia vary according to type and severity.
Neonatal symptoms of PA/IVS:
Cyanosis appears immediately after birth or within hours to days: when the ductus arteriosus begins to close, pulmonary blood flow decreases and cyanosis worsens.
Respiratory distress: rapid breathing, chest retractions, nasal flaring. Apnea in severe cases.
Poor feeding, irritability, lethargy.
Rapid deterioration when the ductus arteriosus closes: pallor, weak pulses, hypotension, metabolic acidosis.
Symptoms of PA/VSD:
Neonatal cyanosis: relatively stable while the ductus arteriosus remains patent, but worsens when it closes.
If pulmonary blood flow via MAPCAs is sufficient, cyanosis may be mild and diagnosis may be delayed.
With age, cyanosis, exercise intolerance, developmental delay and clubbing develop.
When there is pulmonary overcirculation, recurrent pneumonia and symptoms of heart failure may appear.
Common symptoms: abnormal heart sounds (single second heart sound), cyanotic spells (similar to tetralogy of Fallot in PA/VSD).
7. Signs
Physical examination findings in patients with pulmonary atresia:
PA/IVS:
Generalized cyanosis: evident from the perinatal period
Heart murmur: holosystolic murmur due to tricuspid regurgitation (left lower sternal border). Continuous murmur due to ductal flow.
Single second heart sound: no pulmonary component
Hepatomegaly: reflects tricuspid regurgitation and right heart failure
PA/VSD:
Cyanosis: variable in degree (depending on MAPCA supply)
MAPCA murmur: continuous murmur auscultated over the back or lateral chest (when MAPCAs are present)
Single second heart sound (no pulmonary component): typical finding
Clubbing: develops with chronic cyanosis
Heart murmur: holosystolic murmur due to ventricular septal defect, or no murmur (when pressures are equalized)
Electrocardiogram: left ventricular hypertrophy in PA/IVS (reflecting right ventricular hypoplasia). Right ventricular hypertrophy in PA/VSD.
Echocardiography: evaluates pulmonary valve atresia, right ventricular size, tricuspid annulus size, coronary artery fistulas, presence of the ductus arteriosus and so on.
8. Screening
Screening tests for early detection of pulmonary atresia:
Prenatal ultrasound:
If an abnormal four-chamber view (abnormal right ventricular size, pulmonary artery hypoplasia) or abnormal great vessel view is found on the detailed ultrasound at 18–22 weeks of gestation, fetal echocardiography is performed.
In PA/VSD, it is suspected when the pulmonary artery is smaller than the aorta or absent.
When diagnosed prenatally, 22q11.2 FISH/CMA testing is performed as well.
Newborn Pulse Oximetry Screening:
Performed within 24–48 hours after birth. If SpO₂ <95% or the upper-lower limb difference is >3%, echocardiography is performed immediately.
Caution is needed because in PA/VSD with a patent ductus arteriosus and sufficient MAPCA flow, initial SpO₂ may be measured as near-normal and the case may be missed on screening.
When there is a family history or risk factors:
If there are risk factors such as a congenital heart defect in a previous child, 22q11.2 deletion or maternal diabetes, early fetal echocardiography (14–16 weeks of gestation) is considered.
9. Diagnosis
Diagnosis and preoperative evaluation of pulmonary atresia:
Echocardiography:
The primary diagnostic tool. Confirms pulmonary valve atresia and evaluates right ventricular size and function, tricuspid annulus size (Z-score), presence of coronary artery fistulas (RVCA fistula), direction of ductal flow and confluence of the pulmonary arteries.
In PA/IVS, assessment of RVDCC is most important for the treatment approach.
Cardiovascular CT angiography (CTA):
In PA/VSD, evaluates the number, origin, size and pulmonary artery confluence of MAPCAs in three dimensions. MAPCA anatomy is essential for surgical planning.
The size and branching anatomy of the true pulmonary arteries are also evaluated.
Cardiac Catheterization:
Used for hemodynamic evaluation (right ventricular pressure, pulmonary vascular resistance), coronary angiography (confirmation of RVDCC), MAPCA angiography (PA/VSD) and interventional procedures (RF perforation + balloon dilation).
In PA/IVS, coronary angiography is the standard test for evaluating RVDCC.
MRI: used complementarily for assessment of ventricular volumes and pulmonary artery branch anatomy.
10. Treatment
Treatment of pulmonary atresia differs greatly by type.
Common initial management:
Intravenous PGE1 (prostaglandin E1): maintains patency of the ductus arteriosus. 0.01–0.1 mcg/kg/min.
Treatment of PA/IVS:
Without RVDCC — right ventricular decompression:
Percutaneous radiofrequency perforation (RF perforation) + balloon pulmonary valvuloplasty: opens the pulmonary valve to lower right ventricular pressure and promote right ventricular growth.
Surgical pulmonary valvotomy + BTT shunt: when a percutaneous approach is difficult.
With RVDCC:
Right ventricular decompression is contraindicated. Proceed with single-ventricle palliation (BTT shunt → Glenn → Fontan).
Heart transplantation is considered as the final option.
If the right ventricle grows sufficiently, biventricular repair is possible.
Treatment of PA/VSD:
MAPCA unifocalization: multiple MAPCAs are incorporated into the true pulmonary arteries to create a single pulmonary arterial supply. It is often performed in several stages.
Complete repair: after unifocalization, insertion of a right ventricle-to-pulmonary artery conduit and closure of the ventricular septal defect.
Palliative surgery (Fontan) when complete repair is not possible.
11. Prognosis
The prognosis of pulmonary atresia depends greatly on type, right ventricular size and the presence of RVDCC.
Prognosis of PA/IVS:
Without RVDCC and with a normal or larger right ventricle: good long-term survival after biventricular repair (10-year survival ~80–90%).
With RVDCC: poor prognosis. Single-ventricle palliation or heart transplantation is required, with 10-year survival of about 40–60%.
Tricuspid annulus size (Z-score) is an important indicator for predicting prognosis.
Prognosis of PA/VSD:
When complete repair is possible: 10-year survival about 80–90%.
When MAPCAs are complex and complete repair is not possible: poor prognosis.
With 22q11.2 deletion: overall prognosis is worse due to immunodeficiency, neurodevelopmental disorders and an increased need for reoperation.
Long-term complications:
Conduit stenosis: repeated replacement surgery of the right ventricle-to-pulmonary artery conduit required (on average every 10–15 years)
Recurrent pulmonary artery stenosis, progression of pulmonary vascular disease
Arrhythmias: ventricular and atrial arrhythmias
Right ventricular dysfunction
12. Prevention
Prevention strategies for pulmonary atresia:
Prenatal care:
Detailed prenatal ultrasound (18–22 weeks): fetal cardiac evaluation including the four-chamber view and great vessel views.
If abnormal findings: fetal echocardiography + 22q11.2 FISH/CMA testing.
When diagnosed prenatally, delivery at a tertiary hospital and preparation for PGE1 administration immediately after delivery.
Genetic counseling:
Testing of parents of patients with 22q11.2 deletion: if one parent carries the deletion, the risk is 50% in the next pregnancy.
Sporadic PA/VSD: sibling recurrence risk ~3–4%, so fetal echocardiography is recommended in the next pregnancy.
Newborn screening:
Screening for congenital heart defects with pulse oximetry enables early diagnosis before closure of the ductus arteriosus.
If suspected, immediate echocardiography and PGE1 administration.
Regular follow-up:
Regular echocardiography and electrocardiography after surgery, with cardiac catheterization and CT if needed.
Patients with 22q11.2 deletion need multidisciplinary follow-up across immune, endocrine, neurodevelopmental and mental health domains.
13. References
Hanley FL, et al. Outcomes in critically ill neonates with pulmonary stenosis and intact ventricular septum: a multiinstitutional study. J Am Coll Cardiol. 1993;22(1):183-192. PMID:8509544
Calder AL, et al. Pulmonary atresia with intact ventricular septum: review of the anatomy, diagnosis and natural history. Pediatr Cardiol. 1987;8(3):219-226. PMID:3658424
Alwi M, et al. Pulmonary atresia with intact ventricular septum: percutaneous radiofrequency-assisted valvotomy and balloon dilatation versus surgical valvotomy and Blalock-Taussig shunt. J Am Coll Cardiol. 2000;35(2):468-476. PMID:10676695
Reddy VM, et al. One-stage complete unifocalization in infants: when should the ventricular septal defect be closed? J Thorac Cardiovasc Surg. 1997;113(5):858-868. PMID:9159621
Guleserian KJ, et al. Natural history of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries. Circulation. 2006;113(9):1185-1192. PMID:16505170
Daubeney PE, et al. Pulmonary atresia with intact ventricular septum: predictors of early and medium-term outcome in a population-based study. J Thorac Cardiovasc Surg. 2005;130(4):1071-1075. PMID:16214524
Tchervenkov CI, et al. The nomenclature, definition and classification of hypoplastic left heart syndrome. Cardiol Young. 2000;10(1):67-74. PMID:10696261
Moon-Grady AJ, et al. Is there a role for routine genetic analysis in fetuses with pulmonary atresia/intact ventricular septum? Pediatr Cardiol. 2010;31(8):1187-1195. PMID:20617310
Baffa JM, et al. Coronary artery abnormalities and right ventricular histology in hypoplastic right heart syndrome. J Am Coll Cardiol. 1992;20(2):350-358. PMID:1634672
Powell AJ, et al. Systemic-to-pulmonary collateral vessels and neo-aortic arch obstruction: implications for staging of the arterial switch operation. J Thorac Cardiovasc Surg. 1995;109(5):954-960. PMID:7739253